Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:FGEN NASDAQ:KRRO NASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$3.57-0.3%$3.71$1.30▼$4.75$169.64M0.59172,222 shs250,190 shsFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsKRROKorro Bio$11.61+10.3%$12.35$5.20▼$55.89$151.87M3133,637 shs315,440 shsOGIOrganigram Global$1.06-1.9%$1.26$1.04▼$2.24$152.03M1.43523,720 shs255,366 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene-0.28%+7.53%-3.51%-13.56%+80.30%FGENFibroGen0.00%0.00%0.00%0.00%+26.47%KRROKorro Bio+10.26%+8.30%+3.66%-9.30%-21.92%OGIOrganigram Global-1.85%0.00%-4.93%-24.82%-27.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$3.57-0.3%$3.71$1.30▼$4.75$169.64M0.59172,222 shs250,190 shsFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsKRROKorro Bio$11.61+10.3%$12.35$5.20▼$55.89$151.87M3133,637 shs315,440 shsOGIOrganigram Global$1.06-1.9%$1.26$1.04▼$2.24$152.03M1.43523,720 shs255,366 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene-0.28%+7.53%-3.51%-13.56%+80.30%FGENFibroGen0.00%0.00%0.00%0.00%+26.47%KRROKorro Bio+10.26%+8.30%+3.66%-9.30%-21.92%OGIOrganigram Global-1.85%0.00%-4.93%-24.82%-27.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 3.00Buy$8.00124.09% UpsideFGENFibroGen 2.00Hold$43.00340.12% UpsideKRROKorro Bio 2.92Moderate Buy$16.7143.96% UpsideOGIOrganigram Global 2.33HoldN/AN/ACurrent Analyst Ratings BreakdownLatest FGEN, ADAG, KRRO, and OGI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026OGIOrganigram Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/29/2026KRROKorro Bio Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/19/2026KRROKorro Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.005/18/2026KRROKorro Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.005/18/2026KRROKorro Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.005/8/2026KRROKorro Bio JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/20/2026ADAGAdagene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026KRROKorro Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026ADAGAdagene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.003/13/2026KRROKorro Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $22.003/13/2026KRROKorro Bio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$23.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$7.67M22.06N/AN/A$0.75 per share4.76FGENFibroGen$29.62M1.34N/AN/A($50.89) per share-0.19KRROKorro Bio$6.39M26.20N/AN/A$5.46 per share2.13OGIOrganigram Global$185.07M0.81N/AN/A$1.86 per share0.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$17.61MN/AN/AN/AN/AN/AN/AN/AN/AFGENFibroGen-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/AKRROKorro Bio-$117.26M-$11.67N/AN/AN/A-1,834.48%-117.86%-71.04%8/11/2026 (Estimated)OGIOrganigram Global-$17.70M-$0.13N/A26.50N/A-9.22%-13.41%-9.09%8/12/2026 (Estimated)Latest FGEN, ADAG, KRRO, and OGI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q2 2026OGIOrganigram Global-$0.01-$0.01N/A-$0.01$50.56 million$42.99 million5/7/2026Q1 2026KRROKorro Bio-$1.60-$1.69-$0.09-$1.69$0.76 millionN/A4/1/2026Q4 2025ADAGAdagene-$0.28-$0.0440+$0.2360-$0.0440$17.50 million$3.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.033.073.07FGENFibroGenN/A3.713.60KRROKorro BioN/A8.138.13OGIOrganigram GlobalN/A2.821.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%FGENFibroGen72.71%KRROKorro Bio13.18%OGIOrganigram Global34.63%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%FGENFibroGen3.07%KRROKorro Bio4.80%OGIOrganigram Global0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.39 million37.34 millionNot OptionableFGENFibroGen5704.05 million3.92 millionOptionableKRROKorro Bio7014.42 million13.73 millionNo DataOGIOrganigram Global1,139140.77 million140.64 millionOptionableFGEN, ADAG, KRRO, and OGI HeadlinesRecent News About These CompaniesOrganigram Global Inc (OGI) Raises 2026 Guidance on Sanity AcquisitionMay 31, 2026 | insidermonkey.comBuy this cannabis stock for a double, analyst saysMay 18, 2026 | cantechletter.comCOrganigram Global Inc (OGI) Q2 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...May 13, 2026 | finance.yahoo.comTranscript: OrganiGram Holdings Q2 2026 Earnings Conference CallMay 13, 2026 | uk.finance.yahoo.comOrganiGram Holdings Reports Q2 2026 Results: Full Earnings Call TranscriptMay 13, 2026 | uk.finance.yahoo.comOrganigram Says Vape Weakness Pressures MarginsMay 12, 2026 | benzinga.comOrganiGram (OGI) Reports Q2 Loss, Misses Revenue EstimatesMay 12, 2026 | zacks.comOrganigram Global Files Q2 2026 Results as Sanity Group Deal Extends European Cannabis ReachMay 12, 2026 | tipranks.comOrganigram Reports Second Quarter Fiscal 2026 ResultsMay 12, 2026 | financialpost.comFOrganigram global Q2 earnings previewMay 11, 2026 | msn.comOrganigram Global Sets May 12 Date to Report Q2 2026 ResultsMay 6, 2026 | tipranks.comOrganigram to Report Second Quarter Fiscal 2026 Results on May 12th, 2026May 6, 2026 | financialpost.comFBritish American Tobacco buying at Organigram Global (OGI)May 1, 2026 | theglobeandmail.comOrganigram Global (OGI) Completes EUR 107.3 Million Acquisition of Sanity GroupApril 17, 2026 | finance.yahoo.comOrganigram Global (OGI) Completes EUR 107.3 Million Acquisition of Sanity GroupApril 17, 2026 | insidermonkey.comOrganigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit FacilitiesApril 15, 2026 | financialpost.comFOrganigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit FacilitiesApril 15, 2026 | businesswire.comWeekly Roundup on the Cannabis Sector & Psychedelic SectorApril 6, 2026 | finance.yahoo.comIs Organigram Global Inc. (OGI) Among the 11 Best Marijuana Stocks to Buy Right Now?April 1, 2026 | finance.yahoo.comIs Organigram Global Inc. (OGI) Among the 11 Best Marijuana Stocks to Buy Right Now?April 1, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, ADAG, KRRO, and OGI Company DescriptionsAdagene NASDAQ:ADAG$3.57 -0.01 (-0.28%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.58 +0.01 (+0.14%) As of 06/12/2026 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.FibroGen NASDAQ:FGENFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Korro Bio NASDAQ:KRRO$11.61 +1.08 (+10.26%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$11.46 -0.15 (-1.34%) As of 06/12/2026 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Organigram Global NASDAQ:OGI$1.06 -0.02 (-1.85%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.07 +0.01 (+1.32%) As of 06/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
